ATE402189T1 - Verbindungen und methoden zur wt1-spezifischen immuntherapie - Google Patents

Verbindungen und methoden zur wt1-spezifischen immuntherapie

Info

Publication number
ATE402189T1
ATE402189T1 AT01977493T AT01977493T ATE402189T1 AT E402189 T1 ATE402189 T1 AT E402189T1 AT 01977493 T AT01977493 T AT 01977493T AT 01977493 T AT01977493 T AT 01977493T AT E402189 T1 ATE402189 T1 AT E402189T1
Authority
AT
Austria
Prior art keywords
methods
polypeptide
compounds
specific immunotherapy
compositions
Prior art date
Application number
AT01977493T
Other languages
English (en)
Inventor
Alexander Gaiger
Patricia Mcneill
Molly Smithgall
Gus Moulton
Thomas Vedvick
Paul Sleath
Sally Mossman
Lawrence Evans
A Spies
Jeremy Boydston
Original Assignee
Corixa Corp
Alexander Gaiger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/684,361 external-priority patent/US7115272B1/en
Priority claimed from US09/685,830 external-priority patent/US7329410B1/en
Priority claimed from US09/785,019 external-priority patent/US7144581B2/en
Application filed by Corixa Corp, Alexander Gaiger filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE402189T1 publication Critical patent/ATE402189T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01977493T 2000-10-06 2001-10-03 Verbindungen und methoden zur wt1-spezifischen immuntherapie ATE402189T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/684,361 US7115272B1 (en) 1998-09-30 2000-10-06 Compositions and methods for WT1 specific immunotherapy
US09/685,830 US7329410B1 (en) 1998-09-30 2000-10-09 Compositions and method for WT1 specific immunotherapy
US09/785,019 US7144581B2 (en) 2000-10-09 2001-02-15 Compositions and methods for WT1 specific immunotherapy
US09/938,864 US20030072767A1 (en) 1998-09-30 2001-08-24 Compositions and methods for WT1 specific immunotherapy

Publications (1)

Publication Number Publication Date
ATE402189T1 true ATE402189T1 (de) 2008-08-15

Family

ID=27505400

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01977493T ATE402189T1 (de) 2000-10-06 2001-10-03 Verbindungen und methoden zur wt1-spezifischen immuntherapie

Country Status (13)

Country Link
US (1) US20030072767A1 (de)
EP (1) EP1328287B1 (de)
JP (2) JP4130359B2 (de)
KR (1) KR100858231B1 (de)
CN (1) CN100545174C (de)
AT (1) ATE402189T1 (de)
AU (2) AU9660801A (de)
CA (1) CA2425072C (de)
DE (1) DE60135005D1 (de)
ES (1) ES2311027T3 (de)
MX (1) MXPA03002983A (de)
NZ (1) NZ540397A (de)
WO (1) WO2002028414A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CN1281625C (zh) * 2001-03-22 2006-10-25 株式会社癌免疫研究所 经修饰的wt1肽
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
ES2478446T3 (es) * 2003-06-27 2014-07-22 International Institute Of Cancer Immunology, Inc. Método de selección de pacientes candidatos para la vacuna contra WT1
US20050260217A1 (en) * 2004-03-04 2005-11-24 Corixa Corporation Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof
EP1801211A4 (de) * 2004-09-17 2008-06-11 Nec Corp Hla bindendes peptid, dieses codierendes dna-fragment und rekombinanter vektor
EP2565201B1 (de) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1-HLA-Klasse II-bindende Peptide und Zusammensetzungen und Verfahren damit
WO2007070907A2 (en) * 2005-12-21 2007-06-28 St. Anna Kinderkrebsforschung Therapeutic compositions
RU2435782C2 (ru) 2006-02-22 2011-12-10 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
JP5231997B2 (ja) * 2006-03-29 2013-07-10 株式会社癌免疫研究所 ＷＴ１１７ＡＡ（−）アイソフォーム特異的ｓｉＲＮＡおよびその利用
EP2010209B1 (de) * 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogene wt-1-peptide und verfahren zu ihrer verwendung
AU2012227350C1 (en) * 2006-12-28 2015-11-12 International Institute Of Cancer Immunology, Inc. HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same
RU2481398C2 (ru) 2006-12-28 2013-05-10 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Hla-a*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция
KR101773690B1 (ko) 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
ITTO20070401A1 (it) * 2007-06-07 2008-12-08 Univ Degli Studi Torino Vaccino anti-tumorale
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
US20130288236A1 (en) * 2009-11-11 2013-10-31 Quest Diagnostics Investments Incorporated Wt1 mutations for prognosis of myeloproliferative disorders
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
WO2013018778A1 (ja) * 2011-07-29 2013-02-07 独立行政法人理化学研究所 ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物
US10316332B2 (en) 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
JP6122779B2 (ja) 2011-09-14 2017-04-26 株式会社癌免疫研究所 抗ｗｔ１抗体の測定方法
JP6117515B2 (ja) * 2011-11-01 2017-04-19 国立大学法人名古屋大学 髄膜腫治療用医薬組成物
EP3520810A3 (de) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogene wt-1-peptide und verwendung davon
LT2945647T (lt) 2013-01-15 2021-02-25 Memorial Sloan Kettering Cancer Center Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6250288B2 (ja) * 2013-01-30 2017-12-20 株式会社医学生物学研究所 Ｔ細胞レセプターおよびその利用
US10695385B2 (en) * 2015-06-25 2020-06-30 National University Corporation Kobe University Oral cancer vaccine
EP3735984A1 (de) * 2016-05-27 2020-11-11 Etubics Corporation Neoepitop-impfstoffzusammensetzungen und verfahren zur verwendung davon
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
EP3604325A4 (de) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. Wt1-krebs-antigen-peptid und peptid-konjugat-körper damit
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
KR20240134250A (ko) 2018-01-04 2024-09-06 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
EP3835416A4 (de) * 2018-08-10 2022-06-08 Eutilex Co., Ltd. Verfahren zur herstellung und kryokonservierung von krebsantigenspezifischen cd8+t-zellen
JP7162675B2 (ja) 2018-09-28 2022-10-28 住友ファーマ株式会社 注射用組成物
KR20210090650A (ko) 2018-11-07 2021-07-20 그릿스톤 바이오, 인코포레이티드 알파바이러스 신생항원 벡터 및 인터페론 억제제
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
KR20230009426A (ko) 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
TW202315645A (zh) 2021-08-12 2023-04-16 日商癌免疫研究所股份有限公司 用以處置或預防癌症之醫藥組合物及方法
CN115998851A (zh) * 2022-12-28 2023-04-25 四川康德赛医疗科技有限公司 一种个体化mRNA组合物、载体、mRNA疫苗及其应用
CN117552115B (zh) * 2024-01-12 2024-03-26 天津鲸鹏生物科技有限责任公司 用于诱导肿瘤特异性免疫响应的通用型抗原肽库及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3393867B2 (ja) * 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー ウィルムス腫瘍遺伝子の位置決定と特徴付け
CA2167693C (en) * 1993-07-20 2007-01-30 Ulrich Bogdahn Melanoma-inhibiting protein
KR100752065B1 (ko) * 1998-09-30 2007-08-28 코릭사 코포레이션 Ｗｔ1 특이적 면역요법용 조성물 및 방법
NZ521430A (en) * 2000-02-22 2004-04-30 Corixa Corp Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma

Also Published As

Publication number Publication date
NZ540397A (en) 2008-05-30
CA2425072A1 (en) 2002-04-11
AU2001296608B2 (en) 2007-05-24
JP2008154588A (ja) 2008-07-10
JP4130359B2 (ja) 2008-08-06
CN100545174C (zh) 2009-09-30
EP1328287A1 (de) 2003-07-23
DE60135005D1 (de) 2008-09-04
EP1328287A4 (de) 2005-09-07
WO2002028414A1 (en) 2002-04-11
AU9660801A (en) 2002-04-15
US20030072767A1 (en) 2003-04-17
KR100858231B1 (ko) 2008-09-12
ES2311027T3 (es) 2009-02-01
JP2004510425A (ja) 2004-04-08
CN1505526A (zh) 2004-06-16
CA2425072C (en) 2013-11-26
EP1328287B1 (de) 2008-07-23
WO2002028414B1 (en) 2002-07-18
KR20030081314A (ko) 2003-10-17
MXPA03002983A (es) 2004-12-06

Similar Documents

Publication Publication Date Title
DE60135005D1 (de) Verbindungen und methoden zur wt1-spezifischen immuntherapie
DE60232102D1 (de) Zusammensetzungen und Verfahren zur WT1-spezifischen Immuntherapie
TW200509967A (en) Compositions and methods for WT1 specific immunotherapy
TW200606176A (en) Compositions and methods for wt1 specific immunotherapy
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
DE602004015811D1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
ATE256131T1 (de) Calanolide zur hemmung von btk
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2002047613A3 (en) Immunogenic cancer peptides and uses thereof
ZA202407599B (en) Antibodies that specifically bind to api5 protein
DE50110274D1 (de) Arzneimittel zur immuntherapie maligner tumoren
ATE475710T1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
WO2003024304A3 (en) Detection and treatment of cancers of the liver
MX2024002954A (es) Ensayo de potencia de linfocitos.
TR200302193T4 (tr) Kombinasyon kemoterapisi.
WO2003081250A8 (en) Novel compositions and methods in cancer associated with altered expression of prlr

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties